Prosecution Insights
Last updated: November 04, 2026
Application No. 18/257,014

USE OF PSILOCYBIN IN CANCER TREATMENT

Final Rejection §103§DP
Filed
Jun 12, 2023
Priority
Dec 13, 2020 — provisional 63/124,827 +1 more
Examiner
KETCHAM, KAREN A
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Silo Pharma Inc.
OA Round
2 (Final)
21%
Grant Probability
At Risk
3-4
OA Rounds
1m
Est. Remaining
61%
With Interview

Examiner Intelligence

Grants only 21% of cases
21%
Career Allowance Rate
12 granted / 57 resolved
-38.9% vs TC avg
Strong +40% interview lift
Without
With
+39.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
45 currently pending
Career history
120
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
56.7%
+16.7% vs TC avg
§102
12.7%
-27.3% vs TC avg
§112
21.5%
-18.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 57 resolved cases

Office Action

§103 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of the Claims Claims 1-3, 5-9, 13, 24, 28, 31-35, 37 and 56-58 are pending. Claims 2, 3, 8-9, 28, 31-35, 37, and 56 have been withdrawn. Claims 4, 10-12, 14-23, 25-27, 29, 30, 36, 38-55 have been cancelled. Claim 1 has been amended. Claims 57 and 58 have been added. Claims included in the prosecution are claims 1, 5-7, 13, 24 and 57-58. Withdrawn Objections/Rejections The objection to claim 55 is withdrawn. Upon further consideration, the rejection of claims 1, 4-7, 13, 24 and 55 under 35 U.S.C. § 112(a) for enablement for non-oral methods of treatment is withdrawn. In light of the new amendments to claim 1, the rejection of claims 1, 4-7, 13, 24 and 55 under 35 U.S.C. § 112(a) for enablement of a method to treat proliferative disease is withdrawn. New Rejections Applicants’ amendments have necessitated the following grounds of rejection: Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. § 103 (a) are summarized as follows: Determining the scope and contents of the prior art. Ascertaining the differences between the prior art and the claims at issue. Resolving the level of ordinary skill in the pertinent art. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1, 5-7, 13, 24 and 57-58 is/are rejected under 35 U.S.C. § 103 as being unpatentable over Moudgil et al. (US 20190359651 A1) in view of Londesbrough et al. (US 2023/0023092 A1, filed Apr. 17, 2020). Moudgil discloses a method of detecting neuroinflammation in a subject, comprising administering to the subject a central nervous system homing peptide (title, abstract, [0054], claim 48). Multiple sclerosis (MS) is taught as a chronic debilitating autoimmune disease involving inflammation ([0006]). Moudgil discloses a molecular approach to identify novel markers in inflamed CNS ([0047]). Specifically regarding SEQ ID NO 1, Applicants disclose SEQ ID NO: 1 as having the amino acid sequence KRSS (see Spec., [0042], Table 1). Moudgil provides an isolated central nervous system-homing peptide, wherein the peptide comprises an amino acid motif selected from the group consisting of (SEQ ID NO: 1) KRSS ([0011], pg. 12, sequence listing: Lys Arg Ser Ser) and provides embodiments thereof ([0058]). Moudgil teaches peptide, amino acid, and linker bond; ends or side chains(s) of homing peptide are joined to a scaffold that provides a molecular and either end (C or N-terminus) of a homing peptide can be coupled to the scaffold ([0057]). Compositions comprising the CNS-homing peptide and therapeutically active agent may be used to treat a variety of conditions associated with inflammation of the CNS ([0055]). The targeting peptide can be linked to a therapeutic agent, which may be used to treat neuroinflammation, serve as a “molecular homing device” to release the agent via reversible reductive cleavage of a disulfide bond ([0066-0070]). Moudgil teaches homing peptides distributed in the CNS conjugated with imaging agents which target inflamed CNS, and as the homing peptide target inflamed CNS, such conjugates can serve as good indicators of disease activity, specifically areas of inflammation ([0073]). Moudgil does not teach psilocybin. Londesbrough discloses a method comprising administering an effective amount of crystalline psilocybin to the subject (title, abstract, claim 1). The methods described may be used to treat a variety of diseases, disorders, and while Londesbrough focuses on the benefits of psilocybin in neural plasticity and cognitive function, the disclosure teaches that such benefits extend to subjects that have multiple sclerosis and demyelinating disease of central nervous system ([0025]); in treating central nervous disorders ([0223]). Londesbrough provides a pharmaceutical formulation comprising high purity crystalline psilocybin and one or more pharmaceutically acceptable carriers of excipients ([0172], [0214]). Londesbrough provides pharmaceutical compositions a formulation comprising crystalline psilocybin and one or more pharmaceutically acceptable carriers or excipients ([0213], [0225] see table, capsule, dry powder, solution; [0691] Examples formulation development where psilocybin is at 1.0 % w/w). It would have been prima facie obvious to a person of ordinary skill in the art, ahead of the effective filing date of the claimed invention, to incorporate the psilocybin i.e., therapeutic agent, taught by Londesbrough in the targeting peptide of Moudgil to deliver psilocybin with enhanced targeting. One would be motivated to do so with a reasonable expectation of success because Moudgil provides results that show that peptide KRSS preferentially homed to inflamed spinal cord of EAE mice but not in normal mice, and by extrapolation, in patients with neuroinflammatory conditions of the CNS ([0126]). Moudgil discloses the CNS-homing peptide is capable of application in a kit that includes a pharmaceutical composition ([0098]). Londesbrough et al. teach a method of treating depression in a subject in need thereof (claim 1) and more specifically a depressive disorder due to another medical condition ([0006], [0015]), wherein the subject has multiple sclerosis. Regarding the recitation of “the targeting peptide associated with psilocybin is carried by a liposome” in the last line of claim 1, Moudgil teaches liposome as a drug delivery vehicle ([0069], claims 42, 44). Moudgil discloses wherein the liposome further comprises a therapeutic agent (claim 45); wherein the therapeutic agent is released from the liposome (claim 46); wherein the therapeutic agent is conjugated to the surface of the liposome (claim 47). Regarding claim 5 (i.e., wherein the targeting peptide is a CNS targeting peptide) and regarding claim 6 (i.e., targeting peptide is directly associated with psilocybin), Moudgil teaches in an embodiment, a composition comprising an isolated central nervous system homing peptide and a therapeutically active agent is provided, which can include a drug or prodrug, wherein the peptide and the therapeutically active agent are covalently bound to each other ([0097]). Regarding claim 7 (i.e., covalently), Moudgil provides a homing peptide conjugate, i.e., a homing peptide having an amino acid sequence as described herein linked to one or more moieties (i.e., a physical, chemical, or biological material linked to a peptide) ([0067]). Drug molecules, prodrug molecules, or other therapeutic agents may be linked to a homing peptide via covalent bonds or non-covalent bonds ([0068]). The covalent linking of homing peptides to other components including therapeutic agents can be accomplished using techniques which would be readily apparent to one of ordinary skill in the art, e.g., homing peptides can be linked to molecules via the use of well-known coupling or activation agents ([0079-0080]). In terms of a targeting peptide SEQ ID NO 1 covalently attached to psilocybin, it would have been prima facie obvious, before the effective filing date of the claimed invention, to use the combined teachings of the references to arrive at the claimed invention. The CNS homing peptides taught by Moudgil mirror those in the instant claims. Moudgil teaches CNS-homing peptides combined with therapeutically active agent used to treat a variety of conditions associated with inflammation of the CNS. Moudgil discloses a therapeutic agent associated with the CNS-homing peptide. While Moudgil does not specifically disclose psilocybin as the active agent, Londesbrough teaches that psilocybin is used for treating subjects with neuroinflammatory conditions, and as a therapeutic to treat depressive disorders due to a medical condition (e.g., MS). Therefore, one of ordinary skills in the art would anticipate success in substituting the generic anti-inflammatory disclosed by Moudgil with psilocybin, which is taught by Londesbrough as a therapeutic to treat depression because of its ability to reduce neuroinflammation (Londesbrough [0650]). A simple substitution of one known equivalent element for another obtains predictable results and a person of ordinary skill has good reason to pursue the known options within their technical grasp. If this leads to the anticipated success, it is likely the product not of innovation, but of ordinary skill and common sense (KSR International Co. v. Teleflex, Inc., 550 U.S. 398, 82 USPQ2d 1385 (2007)). Regarding claim 13, Londesbrough teaches, at least one dose of psilocybin is administered to the subject, each dose of psilocybin administered to the subject is a therapeutically effective dose, and the dose of psilocybin is in the range of about 0.1 mg to about 100 mg ([0033], [0230-0248], [0251], claims 60-63). MPEP 2144.05 states that a prima facie case of obviousness exists in the case where the claimed ranges overlap or lie inside ranges disclosed by the prior art. Regarding claim 24, pharmaceutical composition orally, Londesbrough discloses that in some embodiments the psilocybin is administered in an oral dosage form ([0032]). Regarding claim 57, as mentioned above Moudgil et al. disclose that the targeting peptide is conjugated to the surface of a liposome ([0029]). Regarding claim 58, as mentioned above, Moudgil discloses administering intravenously in paragraphs [0046] and [0106]. Londesbrough teach exemplary modes for administration of psilocybin to include intravenous ([0253]). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Co-pending application no. 18/004,546 Claims 1, 5-7, 13, and 24 are provisionally rejected on the grounds of nonstatutory double patenting as being unpatentable over claims 1 and 10 of copending Application No. 18/004,546 (reference application '546). Although the claims at issue are not identical, they are not patentably distinct from each other because they are each directed to overlapping embodiments: a method of treating a disease in a subject by administering a CNS-homing peptide associated with psilocybin and a pharmaceutical composition comprising the same. Furthermore, the sequences of ‘546, represented by SEQ ID NOs: 1-22, are identical to those which are instantly claimed by SEQ ID NOs: 1-22. Therefore, '546 teaches an identical method and composition as what is instantly claimed and instant claims 1, 5-7, 13, and 24 are anticipated by '546 claims 1, 10, and 37. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Co-pending application no. 18/004,400 Claims 1, 5-7, 13, and 24 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 7, 9-10, and 13 of copending Application No. 18/004,400 (reference application '400). Although the claims at issue are not identical, they are not patentably distinct from each other because they are each directed to overlapping embodiments: a method of treating a disease in a subject by administering a CNS-homing peptide associated with psilocybin and a pharmaceutical composition comprising the same. Furthermore, the sequences of '400, represented by SEQ ID NOs: 1-22, are identical to those which are instantly claimed by SEQ ID NOs: 1-22. Copending '400 teaches an identical method and composition as what is instantly claimed and instant claims 1, 5-7, 13, and 24 are anticipated by '400 claims 1, 7, 9-10, and 13. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments Applicants’ arguments are based on newly amended limitations of claim 1 reciting in part “wherein the targeting peptide associated with psilocybin is carried by a liposome” which have been addressed by the new grounds of rejection above. Applicants’ arguments have been fully considered but they are not persuasive. Applicants argue that no motivation was provided to combine psilocybin with a targeting peptide and further argue that by doing so would compromise the drug’s purity of Londesborough et al. (Remarks, pg. 8, para. 3). The Examiner respectfully disagrees and submits that the cited art shows that there would be a reasonable expectation of success because the primary reference recognizes the need for the pharmaceutical composition comprising crystalline psilocybin and one or more pharmaceutically acceptable carriers or excipients (see Londesborough [0213]). Moudgil et al. answers the need to provide a carrier specific to intravenous administering wherein sterile injectable solutions may be prepared by incorporating the pharmaceutical compositions in the required amounts of a powder of the active ingredient ([0110-0111]) to suggest a means by which purity and as recited in the claims, “therapeutically effective amount of a pharmaceutical composition” may be delivered. For these reasons, Applicants’ arguments are found unpersuasive. Conclusion All claims under consideration remain rejected; no claims are allowed. Applicants’ amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no case, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Ketcham whose telephone number is (571)270-5896. The examiner can normally be reached 0830-1630. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Karen A Ketcham/Examiner, Art Unit 1614 /ALI SOROUSH/Supervisory Patent Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Jun 12, 2023
Application Filed
Dec 30, 2025
Non-Final Rejection mailed — §103, §DP
Jun 29, 2026
Response Filed
Sep 10, 2026
Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12593838
STABLE AGROCHEMICAL COMPOSITION
3y 6m to grant Granted Apr 07, 2026
Patent 12533302
SYSTEMS AND METHODS FOR DELIVERY OF ACTIVES & HEALING TISSUE
3y 11m to grant Granted Jan 27, 2026
Patent 12508233
GRAFT COPOLYMERS, METHODS OF FORMING GRAFT COPOLYMERS, AND METHODS OF USE THEREOF
4y 8m to grant Granted Dec 30, 2025
Patent 12178800
SULFORAPHANE-MELATONIN-LIKE COMPOUND
3y 10m to grant Granted Dec 31, 2024
Patent 12097180
SWINE MATERNAL NEONATAL PHEROMONE
4y 0m to grant Granted Sep 24, 2024
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
21%
Grant Probability
61%
With Interview (+39.9%)
3y 6m (~1m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 57 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month